"The ongoing consolidation and globalization of the pharmaceutical industry has led to the emergence of several 'underserved therapeutic areas', where research and development have been abandoned due to low patient numbers and questionable profitability. The mission of SymBio Pharmaceuticals is to develop drugs for patients whose voices are no longer heard within this recent wave of change, thereby providing drugs to the healthcare industry that would otherwise not have been developed. By adopting this patient-oriented approach, SymBio endeavors to shed a ray of hope for those in dire need of treatment through the guiding principle of mutual harmony, spinning an intricate symbiotic relationship between patients, physicians, scientists, regulators and investors."
SymBio's salient approach to drug development negates the necessity of costly and time-consuming investment in pre-clinical or R & D activities; using a 'search engine' comprised of reputable scientists and physicians from the Scientific Advisory Board, an in-house evaluation process has been implemented to search for, identify and assess the most promising drug candidates in the US and EU which are in an advanced stage of clinical development.
We forge new ties with bio-venture firms conducting basic research and clinical development by adopting a global approach, searching for the 'gems' of the biopharmaceutical world in order to develop more effective treatments for some of today's most devastating diseases.
The niche which is being exploited by SymBio pharmaceuticals is the existing pool of drug candidates indicated for 'orphan' or 'orphan-like' diseases that can only be successfully mined by a specialty biopharmaceutical company that is nimble and highly efficient in its approach to drug development; unhampered by the increasing costs and risks associated with drug discovery and preclinical development, SymBio's dexterity in finalizing licensing agreements for only the best drug candidates that the industry has to offer, has proven to be a winning formula.
We provide innovative drugs with a balance of efficacy and safety, optimizing quality of life benefits to alleviate the suffering of patients who have 'fallen through the cracks' of the pharmaceutical industry due to their limited contribution to the 'bottom line' of the industry as a whole. SymBio's mission is to bring together the various players in the pharmaceutical industry in order to ensnare or wrest such patients from their life of despair and suffering, adding value to drugs that otherwise would never have reached the marketplace.
We provide novel drugs desperately sought by patients and healthcare professionals, reinvesting a significant portion of profits being generated into existing company resources; this in turn, will broaden the scope of our search for new drug candidates, and the eventual development of such drugs or medical devices in an expeditious manner. And through our "SymBio Reinvestment Program," profits are also funneled into a 'cyclic' model of return to society which was created with the goal of fulfilling SymBio's societal responsibilities, and promoting further development in crucial areas that have been lagging behind those of other countries, such as refractory disease research, patient care, and training for the next generation of skilled researcher in advanced technologies.
We firmly believe it is possible to realize sustainable organic growth in a specialty biopharmaceutical company by creating and fostering the 'symbiotic' relationship between the five spheres of the healthcare industry: private entrepreneurship, government, physicians, scientists and patients.
This is the image of a pharmaceutical company that we wish to cultivate.